GLP-1 Receptor Agonists Linked to Higher Rates of Nail and Hair Disorders in Study

Patients using glucagon-like peptide-1 receptor agonists experience nail disorders at significantly higher rates than comparable non-users, according to findings presented at the European Academy of Dermatology and Venereology Congress. The multinational cross-sectional investigation examined 575 individuals using drugs such as Ozempic and Wegovy alongside 1,329 control participants with obesity or type 2 diabetes who had never used the therapies across France, the United States, Brazil, and Mexico.

The multinational study presented at the European Academy of Dermatology and Venereology Congress 2026 was conducted with the institutional support of DUCRAY Laboratories.

The data showed that 66 percent of GLP-1 users reported at least one nail problem, compared with 53 percent in the control cohort. The most pronounced disparity involved nail detachment, or onycholysis, which was reported by 39 percent of medication users versus 9 percent of controls, marking a more than four-fold difference. Nail discolouration affected 46 percent of users compared with 17 percent of control participants.

For Onycholysis mechanism, Dr. Bianca Maria Piraccini explained that while weight loss is commonly associated with rough, uneven nail surfaces, onycholysis (nail detachment) is not a sign of low caloric intake or protein deficiency and could be directly related to the drug.

Hair and Scalp Changes Also Noted in Companion Investigation

A companion study evaluating the same participant pool identified elevated rates of hair and scalp complaints among individuals taking the medications. Unusual hair loss was reported by 50 percent of GLP-1 users versus 34 percent of controls, while loss of hair volume or density affected 42 percent compared with 19 percent. Furthermore, hair loss initiating after treatment commencement occurred in 26 percent of users against 12 percent of non-users, and scalp redness was reported approximately three times more frequently.

Researchers highlighted that these dermatological symptoms frequently occurred alongside inflammatory markers such as itchy, red, or flaky scalps, distinguishing the presentation from standard telogen effluvium typically associated with rapid weight loss alone. Prior research has similarly linked GLP-1 therapies to increased risks of alopecia compared with alternative diabetes treatments.

Investigators Caution Against Direct Causation Claims

Study authors emphasized that because the investigations were cross-sectional and relied on patient-reported symptoms, the findings demonstrate statistical associations rather than establishing direct causation. Approximately half of the GLP-1 users noted experiencing nail irregularities prior to initiating their treatment regimens.

Statistical adjustments for pre-existing dermatological conditions and nutritional deficiencies attenuated certain associations, though nail detachment and discolouration persisted at rates two to three times higher among users. Additionally, elevated nail disorder prevalence remained evident even among participants who experienced weight loss, suggesting factors beyond rapid mass reduction may contribute. Researchers have planned prospective trials incorporating standardized dermatological assessments and biological monitoring to track symptom emergence and resolution over time.

Adjusted models yielded specific odds ratios for onycholysis and nail dyschromia. Further analyses incorporating comorbidities and nutritional deficiencies produced adjusted odds ratios.